WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 15, 1393-1396. Review Article ISSN 2277–7105

A REVIEW ON NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS PROMISING ANTICANCER AGENTS

[1*]Kiran Bhausaheb Bahir and [2]Minakshi Onkar Pawar

[1]M Pharm Student KYDSCT Pharmacy Bhusawal.

[2]B Pharm Student Valmik Naik College of Pharmacy Kannad.

Article Received on
19 June 2025,

Revised on 09 July 2025,
Accepted on 29 July 2025,

DOI: 10.20959/wjpr202515-37792

***Corresponding Author**
Kiran Bhausaheb Bahir
M Pharm Student KYDSCT
Pharmacy Bhusawal.

ABSTRACT

Nitrogen-containing heterocycles—such as pyridine, quinoline, indole, triazole, and benzimidazole—play central roles in the design of anticancer agents due to their structural versatility, favorable binding interactions, and favorable pharmacokinetic profiles. This review covers recent advances (2018–2024) in their synthesis, structure–activity relationships (SAR), biological evaluation, and potential clinical translation.

1. INTRODUCTION

Nitrogen-heterocycles comprise more than half of all small-molecule drugs, particularly in oncology. Their ability to interact with kinases, DNA, and enzyme targets makes them staple scaffolds for anticancer drug design MDPI + 10 American Chemical Society Publications + 10 ijaec.rpress.co.in+10. Recent literature focuses on optimizing these scaffolds for potency, selectivity, and reduced toxicity MDPI.

2. Key Classes of Nitrogen-Heterocycles in Anticancer Research

2.1 Quinoline & Quinazoline Analogs

Quinoline derivatives exhibit cytotoxic activity via DNA intercalation and kinase inhibition. For example, a hybrid 1,2,3-triazole-quinoline derivative (compound 108a) showed $IC_{50} \approx 0.59\ \mu M$ against BT-474 breast cancer cells and triggered apoptosis across multiple tumor cell lines MDPI.

Another derivative (compound 111a) acting as a PI3K/mTOR dual inhibitor reached $IC_{50} = 0.80$ nM against PI3Kα and showed in vivo efficacy in glioblastoma models arXiv+15MDPI+15De Gruyter Brill+15.

2.2 Indole, Imidazole & Pyrazole Scaffolds

Indole-based aryl-sulfonylhydrazides have shown promising antiproliferative activity against breast cancer cells, with well-characterized SAR American Chemical Society Publications+1American Chemical Society Publications+1. Pyrazole frameworks linked to benzimidazole or thiazole motifs have yielded cytotoxic hits against leukemia and solid tumor lines MDPIDe Gruyter Brill.

2.3 1,2,4-Triazoles & Hybrid Scaffolds

Triazole hybrids fused to heterocycles (e.g. quinazoline, indole, pyrimidine) have demonstrated enhanced anticancer potency versus their monocyclic counterparts Wikipedia+15PubMed+15ijaec.rpress.co.in+15. Podophyllotoxin hybrids connected via a 1,2,3-triazole linker showed significant cytotoxic effects in HepG2, MCF-7 and other cancer lines Wikipedia.

2.4 Nitrogen-Quinone Heterocycles (e.g., Benzotriazine Di-N-Oxides)

Compounds like tirapazamine selectively activate under hypoxic tumor conditions—producing radicals toxic to hypoxic tumor cores. Despite mixed clinical outcomes, it remains a valuable lead chemotype for hypoxia-targeting drug design Wikipedia.

2.5 Phenanthridine & Aziridine Derivatives

Phenanthridine scaffolds exert cytotoxicity via DNA intercalation and topoisomerase inhibition; several derivatives show strong enzyme inhibition and apoptosis induction in vitro Wikipedia. Aziridine-containing compounds like mitomycin C remain clinically relevant alkylating agents with potent antitumor properties Wikipedia.

3. Structure-Activity Relationships (SAR) Insights

SAR studies indicate that electron-withdrawing substituents (e.g., halogens) on quinoline or triazole moieties enhance potency, while bulky substitutions may reduce activity MDPI. For pyrimidines, certain substituents improve both antioxidant and antiproliferative behavior—suggesting ROS-mediated cell death in tumor lines De Gruyter Brill+3arXiv+3American Chemical Society Publications+3.

4. Biological Evaluation & Preclinical Findings

- Quinoline hybrids (e.g. compound 113b) inhibited acetyl-CoA carboxylase and showed nanomolar IC_{50} values (0.38–0.55 nM) in HepG2, A549, and MDA-MB-231 cells; combination with doxorubicin produced synergistic effects MDPI+1Wikipedia+1.
- Indole arylsulfonylhydrazide derivatives suppressed proliferation in breast cancer cell lines with favorable profiling American Chemical Society Publications+1American Chemical Society Publications+1.
- Triazole-podophyllotoxin hybrids demonstrated effective apoptosis induction in liver, gastric, and breast cancer lines Wikipedia+1MDPI+1.

5. Approved Drugs & Clinical Landscape

FDA-approved nitrogen-heterocyclic anticancer drugs include gefitinib, erlotinib, sorafenib, sunitinib, and axitinib—predominantly quinazoline or pyridine-based kinase inhibitors American Chemical Society Publications. Tirapazamine reached Phase III trials but was not widely adopted due to lack of hypoxia-based patient selection Wikipedia.

6. Challenges & Emerging Directions

Key obstacles include drug resistance, off-target toxicity, and challenges with solubility and bioavailability in bulky hybrid scaffolds (>500 Da) Wikipedia. Future strategies emphasize:

- **Tumor-activated prodrugs** (e.g. hypoxia-selective molecules)
- **Hybrid molecules** combining complementary scaffolds
- **Combination therapies** to boost efficacy
- Integration of **computational design**, **nanocarrier delivery**, and high-throughput screening tools American Chemical Society Publications De Gruyter Brillijaec.rpress.co.in.

7. CONCLUSION

Nitrogen-containing heterocycles remain a vital backbone for anticancer drug discovery. Their structural diversity and tunable pharmacodynamics enable targeting multiple pathways—from kinases to DNA damage and hypoxic tumor microenvironments. Continued innovation in SAR optimization, hybrid scaffold design, and selective activation will drive next-generation therapeutics toward clinical translation.

REFERENCES

1. Lang DK et al., Anticancer Agents Med. Chem., 2020; 20(18): 2150–2168 ijaec.rpress.co.inPubMed+2American Chemical Society Publications+2American Chemical Society Publications+2
2. Hosseinzadeh Z, Ramazani A, Razzaghi-Asl N., Curr. Org. Chem., 2018, 22(23): 2256–2279 American Chemical Society Publications.
3. Kumar A et al., Pharmaceuticals, 2023; 16(2): 299 MDPI.
4. Garuti L, Roberti M, Pizzirani D., Mini-Rev. Med. Chem., 2007, 7(5): on nitrogen quinone prodrugs eurekaselect.com.
5. El-Shershaby A et al., SAR of quinoline derivatives arXiv+15MDPI+15arXiv+15.
6. 1,2,4-tria zole review by Rathod & Kumar 2022 De Gruyter Brill+2PubMed+2PubMed+2.
7. Podophyllotoxin-triazole hybrid medicinal chemistry Wikipedia+1arXiv+1.
8. Sarrosolid SAR for ACC inhibition (compounds 113b) MDPI.
9. Indole arylsulfonylhydrazides anticancer evaluation American Chemical Society Publications+1American Chemical Society Publications+1.
10. Phenanthridine enzyme-inhibition cytotoxicity review Wikipedia.
11. Aziridine-based alkylating agents like mitomycin C Wikipedia.
12. Pyrimidine ROS-mediated cytotoxicity in 3T3 lines arXiv.
13. N-heterocycle medicinal applications from Bentham reviews Bentham Science.
14. Hybrid anticancer scaffolds trends (DeGruyter review) De Gruyter Brill.
15. MDPI molecules review – pentacyclic hybrids MDPI.
16. Biswas T et al., Med. Chem., 2024 on nitrogen-fused heterocycles PubMed.
17. Luo W et al., Eur. J. Med. Chem. 2024 on FDA-approved nitrogen heterocycle drug analysis PubMed+3PubMed+3Bentham Science+3.
18. Pal R et al., Bioorg. Chem., 2024 JAK inhibitor scaffolds SAR PubMed.
19. Arylsulfonylhydrazide SAR details from ACS Omega 2022 American Chemical Society Publications+1American Chemical Society Publications+1.
20. Additional general medicinal chemistry frameworks Bentham Scienceijaec.rpress.co.in.